If you want to know who really controls Coherus Oncology, Inc. (NASDAQ:CHRS), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the ...

Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product launches.

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, everyone. Welcome to BeOne Q2 2025 Earnings Call Webcast. [Operator Instructions] At this time, I would like to turn the call over ...

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting ...

During a livestream yesterday, OpenAI announced GPT-5, alongside a series of interface and usability improvements to its chatbot.

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

AC Milan has issued an official statement informing that Franco Baresi, club legend and current honorary vice president, ...

List today: InfuSystems Holdings INFU: This rapidly growing healthcare services company that provides state-of-the-art electronic continuous ambulatory infusion pumps, supplies and support to oncology ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Hospitals and health systems across the country are working to assess what effect the One Big Beautiful Bill Act will have on their institutions, and the fallout of the bill’s looming Medicaid cuts.

Operator: Good day, and welcome to the InfuSystem Holdings, Inc. Second Quarter Fiscal Year 2025 Financial Results Conference ...